Join the Oncology Voice Network. Join for Free
Hiring Managers Beware: Reverse Rejection Explained!

Hiring Managers Beware: Reverse Rejection Explained!


Share This Article


Hiring Managers Beware Reverse Rejection!

👉 This tip is for hiring managers and recruiters out there. There is a defense mechanism that takes place with candidates that we need to be aware of. I call it reverse rejection. Here’s how it works.

👉 Let’s say a candidate has their first phone interview with the hiring manager on Monday. If they don’t get feedback at least by the end of the week, reverse rejection begins to set in. Reverse Rejection is a defense mechanism that candidates have when they are expecting to be rejected, where they start coming up with reasons why they should reject the company.

👉 The same things happens after a final interview. Let’s say a final interview takes place on Monday, and after the interview, the hiring manager tells the candidate that they will hear back in two weeks. Invariably, by Friday of that first week, if not sooner, I’m getting probed by the candidate for feedback.

👉 If I, their recruiter, respond that I haven't received any feedback or if they go into the weekend with no news, well then, reverse rejection begins to set in.

👉 You see, the candidate heard 2 weeks, understood 2 weeks, but is not emotionally ready to handle a 2 week wait. In preparation for being rejected themselves, they start thinking of all the negative things about the company and spin it in their minds that they really didn’t want the job that badly anyway.

👉 So, what can hiring managers, internal recruiters, and external recruiters do to stop reverse rejection from setting in. What I do is I try to touch base with every candidate I have in process before the weekend. The most reverse rejection happens over the weekend, when they are not preoccupied with work.

👉 I see the best companies, the ones most interested in the candidate experience, aren't trying to hire people who have been rejecting them for the last ten to fourteen days. So they move quickly. They don’t rush, but they move quickly and act decisively.

👉 Was that helpful? If so, subscribe to the channel to not miss any of our other insightful tips, and my team and I are standing by to help you with your next critical hire. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
External control arms in oncology: current use and future directions
OVN Avatar P.S. Mishra-Kalyani, L. Amiri Kordestani, D.R. Rivera, H. Singh, A. Ibrahim, R.A. DeClaro, Y. Shen, S. Tang, R. Sridhara, P.G. Kluetz, J. Concato, R. Pazdur, J.A. Beaver

External control arms in oncology: current use and future directions

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN